Asthma and lower airway diseaseTherapeutic efficacy of omalizumab
References (5)
- et al.
Omalizumab-induced reductions in mast cell FcɛRI expression and function
J Allergy Clin Immunol
(2004) - et al.
The relationship between serum IgE and surface levels of FcɛR on human leukocytes in various diseases: correlation of expression with FcɛRI on basophils but not on monocytes or eosinophils
J Allergy Clin Immunol
(2000)
Cited by (25)
Repositioning of anti-cancer drug candidate, AZD7762, to an anti-allergic drug suppressing IgE-mediated mast cells and allergic responses via the inhibition of Lyn and Fyn
2018, Biochemical PharmacologyCitation Excerpt :Although these drugs have immediate effects in a variety of allergic diseases, antihistamines cause drug resistance due to repeated administration, and corticosteroids can cause side effects by inducing hormone changes in the body [36]. Omalizumab, an anti-IgE drug that interferes with the binding of FcεRI and IgE in mast cells, has an excellent efficacy but has a disadvantage in that it is expensive to patients [37]. Therefore, we are studying drugs that target signaling molecules that are involved in the activation of IgE-mediated mast cells.
Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses
2016, Journal of Allergy and Clinical ImmunologyCitation Excerpt :For individual patients, it is unlikely that reductions in levels of biomarkers, such as free serum IgE or blood cell FcεRI alone, will be sufficient to predict responses to anti-IgE treatment.34 There are many other factors involved, including cellular IgE receptor expression (FcεRI and FcεRII/CD23), specific/total IgE ratios, and cellular sensitivity,35 even before considering local tissue IgE concentrations and permeation of the drug to the tissue site. In conclusion, QGE031 was well tolerated in adults with mild allergic asthma.
Cytomegalic hepatitis in a patient receiving omalizumab
2016, IDCasesCitation Excerpt :That way, it prevents the activation of these cells and the consequent liberation of pro-inflammatory mediators [11–14]. On the other hand, it also causes a gradual reduction of FceRI receptor expression, desensitizing cells to stimulation by allergen [15–17]. Regarded as a relatively safe drug, phase III trials have demonstrated a very low incidence of adverse effects [18,19].
Immuno-evasive tactics by schistosomes identify an effective allergy preventative
2015, Experimental ParasitologyAnti-Immunoglobulin E Therapy
2014, Middleton's Allergy: Principles and Practice: Eighth EditionMonitoring free serum IgE in severe asthma patients treated with omalizumab
2012, Respiratory MedicineCitation Excerpt :Nevertheless, a long-term trial to test the clinical potential of monitoring free serum IgE in omalizumab patients is warranted. This further trial is important since in vitro results demonstrate down-regulation of FcɛRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE.29 It is tempting to speculate that long-term treatment with anti-IgE may decrease the doses of omalizumab necessary to uphold a sufficient treatment response.
Disclosure of potential conflict of interest: D. MacGlashan receives grant support from the National Institutes of Health.